← Wrivid News

Health & Food

FDA targets March report on mifepristone safety review

The planned study compares about 100,000 users with a similar-sized group and will use FDA Sentinel data. The filing gives a timeline, not results or a decision to change dispensing rules.

By Wrivid News Desk
A file photograph of FDA Building 31 in Silver Spring, Maryland, which houses the Office of the Commissioner and the Office of Regulatory Affairs.
A file photograph of FDA Building 31 in Silver Spring, Maryland, which houses the Office of the Commissioner and the Office of Regulatory Affairs.File photo: U.S. Food and Drug Administration (public domain, via Wikimedia Commons) · file details · Public domain, U.S. federal government work; unmodified file photo

Executive summary

  • Timeline: In a status report dated Oct. 7, FDA said it expects the study results by mid-December 2026 and plans to finish evaluating them and writing a report no later than March 2027. These are agency estimates, not reported findings.[1][2]
  • Study design: The study compares safety outcomes in approximately 100,000 people using mifepristone with misoprostol through 70 days of pregnancy and a similarly sized comparison group receiving a surgical abortion. FDA says it will use Sentinel data and additional sources, and will adjust for baseline differences.[1]
  • Separate review: FDA is also reviewing the drug’s Risk Evaluation and Mitigation Strategy and related citizen petitions, including requests to restore an in-person dispensing requirement. The agency says it will decide after its review whether any changes are necessary.[1][2]

The Food and Drug Administration told a federal judge it expects to have results from its mifepristone safety study by mid-December 2026. The agency then plans to evaluate the results and complete a written report no later than March 2027. The dates are FDA’s projected schedule in a status report filed in a Louisiana case, not findings from the study or a court-ordered deadline for a final agency decision.[1][2]

The filing supplies a timetable but reports no study results. The judge had stayed the case while FDA completes its review and directed the agency to provide an update on its process and timeframe.[1]

FDA says the study will compare the safety profile of mifepristone used with misoprostol through 70 days of pregnancy with surgical abortion through the same period. The agency describes approximately 100,000 people in each group and says analyses will measure and compare the frequency of safety outcomes while adjusting for baseline differences.[1]

The agency says it is drawing on data held by partners in its Sentinel system and gathering additional data from outside that system. It is also conducting a TreeScan analysis, a statistical data-mining method FDA says can look for safety concerns not identified in advance. Results from that analysis are expected on the same timeline as the study report.[1]

The status report says FDA’s broader review of the mifepristone Risk Evaluation and Mitigation Strategy also includes multiple citizen petitions. Some petitioners seek to restore requirements previously removed, including dispensing only in certain health care settings. The report says the agency will review the submitted materials and decide whether changes to the program are necessary after completing its study and review.[1][2]

The filing does not announce new restrictions or a change to the drug’s current terms. The Associated Press reported that the timeline drew criticism from abortion opponents who want the drug’s use curtailed. The agency’s ultimate decision remains pending.[1][2]